TITLE

Four-cycle ABVD more toxic for older patients with Hodgkin's lymphoma

PUB. DATE
May 2013
SOURCE
Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p31
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the findings of a study which revealed a significant dose reduction, delay in treatment, toxicity and treatment-associated mortality among patients aged at least 60 years with early-stage Hodgkins lymphoma who took four cycles of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine.
ACCESSION #
88255721

 

Related Articles

  • Non-Hodgkin Lymphoma. Fox, Christopher; Mead, Adam; Sellar, Rob // Current Medical Literature: Leukemia & Lymphoma;2011, Vol. 19 Issue 4, p110 

    The article discusses the findings of several studies on non-Hodgkin lymphoma. One study examined indolent mantle cell leukemia (MCL) with isolated blood and bone marrow involvement. Another examined the risk of central nervous system relapse in diffuse large B-cell lymphoma (DLBCL) patients. A...

  • CSF-1R Expression in Tumor-Associated Macrophages Is Associated With Worse Prognosis in Classical Hodgkin Lymphoma. Young Wha Koh; Chansik Park; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh // American Journal of Clinical Pathology;Apr2014, Vol. 141 Issue 4, p573 

    Objectives: The aim of this study was to determine the prognostic relevance of colony-stimulating 1 receptor (CSF-1R) expression in both Hodgkin/Reed-Sternberg (HRS) cells and the surrounding cells (non-HRS cells) in patients with classical Hodgkin lymphoma (CHL) . Methods: Diagnostic tissues...

  • G-CSF plus PBPCT offers cost-effective alternative to ABMT.  // Formulary;Nov95, Vol. 30 Issue 11, p652 

    Suggests that the combination of peripheral blood progenitor cell (PBPC) transplantation and colony-stimulating factor (G-CSF) is a cost effective treatment for Hodgin's disease or lymphoma. Comparison with autologous bone marrow transplantation costs; Comments of Thomas Smith of Virginia...

  • Non-hodgkin's lymphoma. Patlak, Margie // FDA Consumer;Dec96, Vol. 30 Issue 10, p20 

    Reports that the Non-Hodgkin's (NHL) lymphoma is now the sixth most common cancer in the United States. Symptoms of NHL; Treatments for NHL; How doctors determine the stage of the cancer according to the number and location of tumors; What procedure is used to determine the type of NHL cancer;...

  • Discussion about treatment of early-stage Hodgkin's lymphoma needed radiation oncologist. Prosnitz, Leonard R.; Kelsey, Christopher // Hem/Onc Today;4/10/2013, Vol. 14 Issue 7, p7 

    The article discusses the highlights of a roundtable discussion about the treatment of early-stage Hodgkin's lymphoma featured on the December 25, 2013 issue of "Hematology/Oncology Today."

  • Naturopathy Complements Chemo. Bennett, Peter // Alive: Canada's Natural Health & Wellness Magazine;Apr2002, Issue 234, p46 

    Focuses on the importance of naturopathy in reducing the side effects of conventional therapy in treating Hodgkin's lymphoma. Strategies for managing health challenges; Comprehensiveness of the natural program to fight cancer; Risk of chemotherapy treatment for cancer.

  • Doxorubicin liposomal.  // Reactions Weekly;2/4/2012, Issue 1387, p17 

    The article describes the case of a 37-year-old man developed palmoplantar erythrodysaesthesia (PPE) while receiving pegylated (PLD) and non-pegylated doxorubicin (NPLD) liposomal for Hodgkin's disease.

  • Osteosarcoma in an adolescent previously treated for Hodgkin's Disease. Kourti, M.; Sidi, V.; Papakonstantinou, E. // Hippokratia;2014, Vol. 18 Issue 1, p96 

    A letter to the editor is presented which reveals the development of a secondary tumor or osteosarcoma in an adolescent after treatment for Hodgkin's disease.

  • Non-Hodgkin's lymphoma trials in elderly look beyond CHOP. McNeil, Caroline; McNeil, C // JNCI: Journal of the National Cancer Institute;02/18/98, Vol. 90 Issue 4, p266 

    Presents information on researchers' launch of a randomized trial for elderly patients with intermediate-grade non-Hodgkin's lymphoma (NHL) in December, 1997. Why this trial was launched; Indepth look at the trial; Statistical information on the increase of NHL; Comments from Joseph M. Connors,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics